Stock listing
NASDAQ:SLRN Acelyrin, Inc. Stock
Follow Acelyrin, Inc. into a list and get an email when it puts out news.
Last close · NASDAQ:SLRN
$2.27 USD
Close on May 22, 2025 · No longer trades
- Lowest – highest close
- $1.89 – $28.82 USDSince May 5, 2023 · lowest Feb 4, 2025 · highest Aug 22, 2023
Delisted NASDAQ:SLRN no longer trades. Its last trading date is unknown. Company history and updates stay available on this page.
- Ticker
- NASDAQ:SLRN
- Asset type
- Stock
- Exchange
- NASDAQ
- Currency
- USD
Acelyrin, Inc. on 6ix
- Calls
- 3 calls with a replay · 3 with a transcript · latest Nov 13, 2024
- Decks
- 9 decks · latest Apr 29, 2025
Events
| Call | When | Status |
|---|---|---|
| Acelyrin (SLRN) Q3 2024 Earnings Call | Wed, Nov 13, 2024 · 4:30 PM ET | Replay |
| Acelyrin (SLRN) Q2 2024 Earnings Call | Tue, Aug 13, 2024 · 5:00 PM ET | Replay |
| Acelyrin (SLRN) Q3 2023 Earnings Call | Tue, Nov 07, 2023 · 4:30 PM ET | Replay |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Merger or Acquisition (April 2025) | Merger or acquisition | 36 slides | Apr 29, 2025 |
| Merger or Acquisition (April 2025) | Merger or acquisition | 29 slides | Apr 21, 2025 |
| Merger or Acquisition (March 2025) | Merger or acquisition | 6 slides | Mar 25, 2025 |
| Merger or Acquisition (March 2025) | Merger or acquisition | 10 slides | Mar 18, 2025 |
| Merger or Acquisition (March 2025) | Merger or acquisition | 35 slides | Mar 11, 2025 |
| Merger or Acquisition (March 2025) | Merger or acquisition | 7 slides | Mar 6, 2025 |
| Merger or Acquisition (March 2025) | Merger or acquisition | 31 slides | Mar 6, 2025 |
| Merger or Acquisition (February 2025) | Merger or acquisition | 18 slides | Feb 6, 2025 |
| Technical Presentation (March 2024) | Technical | 31 slides | Mar 11, 2024 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Patrick Machado Other companies: Alumis Inc. (Independent Board Member · Since at least Jun 27, 2024); Xenon Pharmaceuticals Inc. (Director · Since at least Nov 5, 2020); Arcus Biosciences, Inc. (Board Member · Since at least Dec 10, 2019); Adverum Biotechnologies Inc (Director · Since at least Mar 14, 2017); Turnstone Biologics Corp. (Director · Jul 20, 2023 – Jul 20, 2023 · Past); Roivant Sciences Ltd. (Director · Oct 1, 2021 – Oct 1, 2021 · Past); Principia Biopharma Inc (Director · Jun 11, 2019 – Sep 28, 2020 · Past); Turning Point Therapeutics Inc (Director · May 13, 2019 – Aug 17, 2022 · Past); Endocyte Inc (Director · Feb 27, 2018 – Dec 21, 2018 · Past); Sio Gene Therapies Inc (Director · Jul 17, 2017 – Jul 17, 2017 · Past); Rocket Pharmaceuticals, Inc. (Director · Aug 17, 2016 – Jun 20, 2017 · Past); Scynexis, Inc. (Director · Sep 24, 2015 – Jan 2, 2019 · Past); Chimerix Inc (Director · Jun 20, 2014 – Jun 9, 2023 · Past); Medivation Inc (Director · Jun 5, 2007 – Sep 28, 2016 · Past) | Director · May 4, 2023 – May 21, 2025 · Past |
| Beth C Seidenberg Other companies: Latigo Biotherapeutics, Inc. (Director · Since at least Aug 6, 2026); Kyverna Therapeutics, Inc. (Director · Since at least Feb 7, 2024); Sagimet Biosciences Inc. - Series A (Director · Since at least Jul 13, 2023); Vera Therapeutics, Inc. (Director · Since at least May 13, 2021); Progyny, Inc. (Director · Oct 24, 2019 – May 23, 2024 · Past); Armo Biosciences Inc. (Director · Jan 25, 2018 – Jun 22, 2018 · Past); Atara Biotherapeutics, Inc. (Director · Oct 15, 2014 – May 31, 2023 · Past); Epizyme Inc (Director · May 30, 2013 – Jun 30, 2019 · Past); Tesaro Inc (Director · Jun 27, 2012 – Jan 22, 2019 · Past) | Director · May 4, 2023 – May 21, 2025 · Past |
| Dawn Svoronos Other companies: Adverum Biotechnologies Inc (Director · Since at least Dec 9, 2020); Xenon Pharmaceuticals Inc. (Director · Since at least Sep 27, 2016); Global Blood Therapeutics Inc (Director · Dec 19, 2018 – Oct 5, 2022 · Past); Endocyte Inc (Director · May 3, 2018 – Dec 21, 2018 · Past); PTC Therapeutics, Inc. (Director · Jun 10, 2016 – Jun 9, 2022 · Past); Medivation Inc (Director · Apr 22, 2013 – Sep 28, 2016 · Past) | Director · May 4, 2023 – May 21, 2025 · Past |
| David E Goel Other companies: Alumis Inc. (Director · Jun 27, 2024 – May 21, 2025 · Past); Zentalis Pharmaceuticals, Inc. (Director · Apr 3, 2020 – Apr 3, 2020 · Past); Adaptive Biotechnologies Corporation (Director · Jun 26, 2019 – Feb 15, 2021 · Past); Popular, Inc. (Director · Feb 12, 2012 – May 8, 2018 · Past) | Director · May 4, 2023 – May 21, 2025 · Past |
| Henry Gosebruch Other companies: ANI Pharmaceuticals, Inc. (Director · Since at least Aug 19, 2026); Neumora Therapeutics, Inc. (President & CEO, Director · Sep 14, 2023 – Feb 14, 2024 · Past); Aptinyx Inc (Director · May 6, 2019 – May 26, 2022 · Past); AbbVie Inc. (EVP, Chief Strategy Officer · Oct 30, 2017 – May 16, 2022 · Past) | Director · May 4, 2023 – May 21, 2025 · Past |
| Lynn A. Tetrault Other companies: Alumis Inc. (Director · Since at least May 21, 2025); NeoGenomics, Inc. (Director · Since at least Jun 2, 2021); Rhythm Pharmaceuticals, Inc. (Director · Since at least Dec 9, 2020) | Director · Dec 18, 2023 – May 21, 2025 · Past |
| Gil Labrucherie Other companies: Septerna, Inc. (Chief Financial Officer · Since at least Jan 6, 2025); Rezolute, Inc. (Director · Since at least Jan 23, 2024) | CFO and CBO · Oct 4, 2023 – Aug 31, 2024 · Past |
| Amar Murugan Other companies: Atara Biotherapeutics, Inc. (EVP, Chief Legal Officer · Apr 20, 2020 – Aug 16, 2024 · Past) | Chief Legal Officer · Nov 13, 2024 – May 21, 2025 · Past |
| Bruce C. Cozadd Other companies: Jazz Pharmaceuticals plc (Director · Since at least Oct 1, 2020) | Director · May 4, 2023 – May 21, 2025 · Past |
| Melanie Gloria Other companies: Immunovant, Inc. (Chief Operating Officer · Since at least Nov 7, 2024) | Chief Operating Officer · May 4, 2023 – May 23, 2024 · Past |
All 15 people
| Person | Seat |
|---|---|
| Mina Kim Other companies: Zymergen Inc (Chief Legal Officer · May 2, 2022 – Sep 2, 2022 · Past) | Chief Executive Officer, Director · May 4, 2023 – May 21, 2025 · Past |
| Sanam Pangali Other companies: Alumis Inc. (Chief Legal Officer · Since at least Jul 4, 2025) | CLO & Head of People · May 9, 2024 – May 23, 2024 · Past |
| Paul Peloso | Chief Medical Officer · May 4, 2023 – Oct 4, 2023 · Past |
| Ronald Oyston | Chief People Officer · Jan 9, 2024 – Jan 9, 2024 · Past |
| Shephard Mpofu | Chief Medical Officer · May 9, 2024 – May 21, 2025 · Past |
Log in to ask 6ix AI your own questions about Acelyrin, Inc.